BeiGene drug fails comparative study against AbbVie: J&J rival Imbruvica

BeiGene Ltd said on Monday a late-stage trial showed that its cancer treatment did not meet the main goal of proving superior to Imbruvica, a rival drug from Johnson & Johnson and AbbVie Inc.